||December 18, 2002
||David Rowe, Vice President, New Business Development, 317-580-8288, email@example.com
Carmel, IN. - SePRO Corporation announces the purchase from Eli Lilly and Company of the worldwide rights to develop and market the compound Spinosad for the control of lice in human health.
Human lice, including head lice, are a significant problem in health care. In 2001, almost every school district in the United States had problems with head lice. The Spinosad technology was discovered by Lilly in 1985, and has been developed in collaboration with Dow AgroSciences, a division of The Dow Chemical Company.
William H. Culpepper, President of SePRO, announced the purchase, and indicated that he was pleased Lilly had chosen SePRO for the development and ultimate commercialization of this compound. “Lilly’s analysis had indicated the potential in human health fell below their threshold for product development, however, the compound is a perfect match with SePRO’s size and capabilities.” SePRO has formed an affiliated company, ParaPRO LLC to develop products from this technology. ParaPRO will be responsible for filing an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA), and for the design and execution of a clinical development program to demonstrate human safety and efficacy.
SePRO is also pleased this transaction supports the Central Indiana Life Sciences Initiative. This Initiative encourages the development of technology from major Indiana Life Sciences companies, for the creation and growth of new companies in Central Indiana.
David Rowe has joined ParaPRO as Vice President, New Business Development.
ParaPRO LLC was founded in 2002 when SePRO Corporation of Carmel, IN purchased the worldwide rights to develop and market Spinosad for the control of lice in human health from Eli Lilly and Company. The compound is currently in clinical trials at multiple sites across the United States. More information on ParaPRO can be found at www.parapro.com.
SePRO Corporation is recognized as an industry leader in providing the highest level of technical service to customers who operate in specialty markets of the USA. To learn more about SePRO Corporation, its products, services and technologies, call 1-800-419-7779 or visit the SePRO web site at www.sepro.com.
Ask your doctor if Natroba™ Topical Suspension is right for you or your child.
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients
six (6) months of age and older.
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
- Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
- Wash personal care items such as combs, brushes, and hair clips in hot water
A fine-toothed comb or special nit comb may be used to remove dead lice and nits.
IMPORTANT SAFETY INFORMATION
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months.
Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates
and low birth-weight infants. Most common adverse events were: application site redness (3%), eye redness (2%) and application
site irritation (1%).
Consult the Patient Information, Full Prescribing Information and your doctor for more complete information on Natroba™ Topical Suspension.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.